Breast Cancer Liquid Biopsy Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032
CHAPTER 1. Industry Overview of Breast Cancer Liquid Biopsy Market
1.1. Definition and Scope
1.1.1. Definition of Breast Cancer Liquid Biopsy
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Breast Cancer Liquid Biopsy Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Breast Cancer Liquid Biopsy Market By Circulating Biomarkers
1.2.3. Breast Cancer Liquid Biopsy Market By Application
1.2.4. Breast Cancer Liquid Biopsy Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Source
2.2.2. Primary Source
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Breast Cancer Liquid Biopsy Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Breast Cancer Liquid Biopsy Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Price Trend of Key Raw Material
3.8.1. Raw Material Suppliers
3.8.2. Proportion of Manufacturing Cost Structure
3.8.2.1. Raw Material
3.8.2.2. Labor Cost
3.8.2.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2022
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2022
4.2. R&D Status of Major Manufacturers in 2022
CHAPTER 5. Breast Cancer Liquid Biopsy Market By Circulating Biomarkers
5.1. Introduction
5.2. Breast Cancer Liquid Biopsy Revenue By Circulating Biomarkers
5.2.1. Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast, By Circulating Biomarkers, 2020-2032
5.2.2. Circulating Tumor Cells (CTCs)
5.2.2.1. Circulating Tumor Cells (CTCs) Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.3. Extracellular Vesicles (EVs)
5.2.3.1. Extracellular Vesicles (EVs) Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.4. Circulating Cell-free DNA (cfDNA)
5.2.4.1. Circulating Cell-free DNA (cfDNA) Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.5. Others
5.2.5.1. Others Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 6. Breast Cancer Liquid Biopsy Market By Application
6.1. Introduction
6.2. Breast Cancer Liquid Biopsy Revenue By Application
6.2.1. Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast, By Application, 2020-2032
6.2.2. Early Detection/Screening
6.2.2.1. Early Detection/Screening Market Revenue (USD Million) and Growth Rate (%), 2020-2032
6.2.3. Treatment Selection
6.2.3.1. Treatment Selection Market Revenue (USD Million) and Growth Rate (%), 2020-2032
6.2.4. Diagnosis
6.2.4.1. Diagnosis Market Revenue (USD Million) and Growth Rate (%), 2020-2032
6.2.5. Monitoring
6.2.5.1. Monitoring Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 7. North America Breast Cancer Liquid Biopsy Market By Country
7.1. North America Breast Cancer Liquid Biopsy Market Overview
7.2. U.S.
7.2.1. U.S. Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Circulating Biomarkers, 2020-2032
7.2.2. U.S. Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Application, 2020-2032
7.3. Canada
7.3.1. Canada Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Circulating Biomarkers, 2020-2032
7.3.2. Canada Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Application, 2020-2032
7.4. North America PEST Analysis
CHAPTER 8. Europe Breast Cancer Liquid Biopsy Market By Country
8.1. Europe Breast Cancer Liquid Biopsy Market Overview
8.2. U.K.
8.2.1. U.K. Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Circulating Biomarkers, 2020-2032
8.2.2. U.K. Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Application, 2020-2032
8.3. Germany
8.3.1. Germany Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Circulating Biomarkers, 2020-2032
8.3.2. Germany Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Application, 2020-2032
8.4. France
8.4.1. France Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Circulating Biomarkers, 2020-2032
8.4.2. France Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Application, 2020-2032
8.5. Spain
8.5.1. Spain Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Circulating Biomarkers, 2020-2032
8.5.2. Spain Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Application, 2020-2032
8.6. Rest of Europe
8.6.1. Rest of Europe Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Circulating Biomarkers, 2020-2032
8.6.2. Rest of Europe Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Application, 2020-2032
8.7. Europe PEST Analysis
CHAPTER 9. Asia Pacific Breast Cancer Liquid Biopsy Market By Country
9.1. Asia Pacific Breast Cancer Liquid Biopsy Market Overview
9.2. China
9.2.1. China Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Circulating Biomarkers, 2020-2032
9.2.2. China Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Application, 2020-2032
9.3. Japan
9.3.1. Japan Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Circulating Biomarkers, 2020-2032
9.3.2. Japan Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Application, 2020-2032
9.4. India
9.4.1. India Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Circulating Biomarkers, 2020-2032
9.4.2. India Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Application, 2020-2032
9.5. Australia
9.5.1. Australia Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Circulating Biomarkers, 2020-2032
9.5.2. Australia Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Application, 2020-2032
9.6. South Korea
9.6.1. South Korea Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Circulating Biomarkers, 2020-2032
9.6.2. South Korea Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Application, 2020-2032
9.7. Rest of Asia-Pacific
9.7.1. Rest of Asia-Pacific Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Circulating Biomarkers, 2020-2032
9.7.2. Rest of Asia-Pacific Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Application, 2020-2032
9.8. Asia Pacific PEST Analysis
CHAPTER 10. Latin America Breast Cancer Liquid Biopsy Market By Country
10.1. Latin America Breast Cancer Liquid Biopsy Market Overview
10.2. Brazil
10.2.1. Brazil Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Circulating Biomarkers, 2020-2032
10.2.2. Brazil Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Application, 2020-2032
10.3. Mexico
10.3.1. Mexico Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Circulating Biomarkers, 2020-2032
10.3.2. Mexico Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Application, 2020-2032
10.4. Rest of Latin America
10.4.1. Rest of Latin America Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Circulating Biomarkers, 2020-2032
10.4.2. Rest of Latin America Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Application, 2020-2032
10.5. Latin America PEST Analysis
CHAPTER 11. Middle East & Africa Breast Cancer Liquid Biopsy Market By Country
11.1. Middle East & Africa Breast Cancer Liquid Biopsy Market Overview
11.2. GCC
11.2.1. GCC Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Circulating Biomarkers, 2020-2032
11.2.2. GCC Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Application, 2020-2032
11.3. South Africa
11.3.1. South Africa Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Circulating Biomarkers, 2020-2032
11.3.2. South Africa Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Application, 2020-2032
11.4. Rest of Middle East & Africa
11.4.1. Rest of Middle East & Africa Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Circulating Biomarkers, 2020-2032
11.4.2. Rest of Middle East & Africa Breast Cancer Liquid Biopsy Revenue (USD Million) and Forecast By Application, 2020-2032
11.5. Middle East & Africa PEST Analysis
CHAPTER 12. Player Analysis Of Breast Cancer Liquid Biopsy Market
12.1. Breast Cancer Liquid Biopsy Market Company Share Analysis
12.2. Competition Matrix
12.2.1. Competitive Benchmarking Of Key Players By Price, Presence, Market Share, And R&D Investment
12.2.2. New Product Launches and Product Enhancements
12.2.3. Mergers And Acquisition In Global Breast Cancer Liquid Biopsy Market
12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 13. Company Profile
13.1. Guardant Health, Inc.
13.1.1. Company Snapshot
13.1.2. Business Overview
13.1.3. Financial Overview
13.1.3.1. Revenue (USD Million), 2022
13.1.3.2. Guardant Health, Inc. 2022 Breast Cancer Liquid Biopsy Business Regional Distribution
13.1.4. Product/Service and Specification
13.1.5. Recent Developments & Business Strategy
13.2. Freenome Holdings, Inc.
13.3. Biocept, Inc.
13.4. Illumina, Inc.
13.5. GRAIL, Inc.
13.6. Qiagen N.V.
13.7. Roche Holding AG
13.8. Thermo Fisher Scientific Inc.
13.9. Exact Sciences Corporation
13.10. Natera, Inc.
Frequently Asked Questions
What was the market size of the global breast cancer liquid biopsy in 2022?
The market size of breast cancer liquid biopsy was USD 335 Million in 2022.
What is the CAGR of the global breast cancer liquid biopsy market from 2023 to 2032?
The CAGR of breast cancer liquid biopsy is 22.5% during the analysis period of 2023 to 2032.
Which are the key players in the breast cancer liquid biopsy market?
The key players operating in the global market are including Guardant Health, Inc., Freenome Holdings, Inc., Biocept, Inc., Illumina, Inc., GRAIL, Inc., Qiagen N.V., Roche Holding AG, Thermo Fisher Scientific Inc., Exact Sciences Corporation, and Natera, Inc.
Which region dominated the global breast cancer liquid biopsy market share?
North America held the dominating position in breast cancer liquid biopsy industry during the analysis period of 2023 to 2032.
Which region registered fastest CAGR from 2023 to 2032?
Asia-Pacific region exhibited fastest growing CAGR for market of breast cancer liquid biopsy during the analysis period of 2023 to 2032.
What are the current trends and dynamics in the global breast cancer liquid biopsy industry?
The current trends and dynamics in the breast cancer liquid biopsy market growth include increasing prevalence of breast cancer, demand for non-invasive diagnostic tools, and technological advancements in liquid biopsy platforms.
Which circulating biomarkers held the maximum share in 2022?
The circulating cell-free DNA biopsy circulating biomarkers held the maximum share of the breast cancer liquid biopsy industry.
Select Licence Type
Connect with our sales team
Why Acumen Research And Consulting
100%
Customer Satisfaction
24x7
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
